Accueil・Liste d'Actions・MacroGenics Inc

MacroGenics Inc

Fermé

SecteurSoins de santé

4.01 -1.96

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.03

Max

4.09

Chiffres clés
By Trading Economics
Revenu	56M 20M
Ventes	12M 33M
BPA	-0.27
Marge bénéficiaire	59.439
Employés	293
EBITDA	16M -14M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+70.73% upside

Dividendes
By Acuity
Prochains Résultats	10 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-702K 259M
Ouverture précédente	5.97
Clôture précédente	4.01

Sentiment de l'Actualité

By Acuity

29%

71%

84 / 340 Classement par Healthcare

MacroGenics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 août 2026, 20:06 UTC

MacroGenics shares are lower today, pulling back from earlier session highs amid rising crude oil prices and increased U.S. Treasury yields.

19 août 2026, 21:01 UTC

MacroGenics Inc shares are lower in after-market trading, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

18 août 2026, 19:46 UTC

MacroGenics Inc. shares are gaining during Tuesday's session, despite earlier pulling back from a session high amid rising Treasury yields and inflation concerns.

17 août 2026, 19:51 UTC

MacroGenics Inc shares are lower today amid unusual volatility, having hit a session low before a brief recovery. No specific news was identified.

14 août 2026, 19:21 UTC

Shares of MacroGenics Inc. are lower today amid cautious investor sentiment following a drop in U.S. retail sales, impacting expectations for Federal Reserve interest rate hikes.

13 août 2026, 21:01 UTC

News

MacroGenics shares declined after reporting Q2 2026 results, which included a workforce reduction and a pro forma cash position of $327 million.

12 août 2026, 19:46 UTC

Social Media

MacroGenics Inc received a $10 million milestone payment, boosting investor sentiment and contributing to shares trading higher during Wednesday's session.

11 août 2026, 22:26 UTC

News

MacroGenics shares rise after Gilead Sciences exercises licensing option, triggering a $10 million payment and potential for $1.6 billion in future milestones.

4 août 2026, 19:46 UTC

MacroGenics shares are lower today, retracing from a session high amid a broader market decline linked to falling crude oil prices.

31 juil. 2026, 20:06 UTC

MacroGenics Inc. shares are lower today amid rising U.S. Treasury yields and inflation concerns, continuing a downward trend since Thursday's close.

29 juil. 2026, 20:09 UTC

MacroGenics Inc shares are lower today, continuing a downward trend since Tuesday's close. The stock showed early gains before sharply reversing course.

28 juil. 2026, 17:03 UTC

MacroGenics Inc shares are lower today amid broader market volatility. The stock remains near the lower end of its one-month range.

27 juil. 2026, 20:01 UTC

News

MacroGenics shares are higher as analysts remain optimistic about MGC026's potential, supported by a strong cash runway projected until 2028.

24 juil. 2026, 20:01 UTC

MacroGenics Inc shares are declining amid broader biotechnology sector weakness, marking four consecutive sessions of losses with no specific company news identified.

22 juil. 2026, 19:51 UTC

MacroGenics Inc is trading lower today, breaking a trend of higher closes. Broader market sentiment is cautious amid rising crude oil prices and geopolitical tensions.

21 juil. 2026, 19:06 UTC

MacroGenics Inc shares are higher, supported by optimism in the semiconductor sector and potential price increases from TSMC by 2027.

Comparaison

Variation de prix

MacroGenics Inc prévision

Objectif de Prix

By TipRanks

70.73% hausse

Prévisions sur 12 Mois

Moyen 7 USD 70.73%

Haut 11 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

84 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.